Prudential Financial’s Revance Therapeutics, Inc. RVNC Stock Holding History

Prudential Financial’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,963	Closed	-$289K	–	2729
2023 Q1	$289K	Buy	+8,963	New	+$279K	﹤0.01%	2274
2022 Q3	–	Sell	-52,084	Closed	-$720K	–	2737
2022 Q2	$720K	Sell	52,084 -83,670	-62%	-$1.29M	﹤0.01%	1951
2022 Q1	$2.65M	Buy	135,754 +52,674	+63%	+$799K	﹤0.01%	1339
2021 Q4	$1.41M	Sell	83,080 -795	-0.9%	-$13.3K	﹤0.01%	1711
2021 Q3	$2.34M	Buy	83,875 +210	+0.3%	+$5.99K	﹤0.01%	1374
2021 Q2	$2.48M	Buy	83,665 +280	+0.3%	+$8.08K	﹤0.01%	1372
2021 Q1	$2.33M	Buy	83,385 +25,026	+43%	+$692K	﹤0.01%	1381
2020 Q4	$1.65M	Sell	58,359 -2,656	-4%	-$68.8K	﹤0.01%	1500
2020 Q3	$1.53M	Sell	61,015 -31,594	-34%	-$828K	﹤0.01%	1449
2020 Q2	$2.26M	Buy	92,609 +39,105	+73%	+$772K	﹤0.01%	1280
2020 Q1	$792K	Buy	+53,504	New	+$1.11M	﹤0.01%	1771

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prudential Financial's RVNC Position: Q2 2023 in Review

Prudential Financial sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2023, closing a stake of 8,963 shares — an estimated $289K sold.

Prudential Financial first reported a position in RVNC in Q1 2020 and held it in 11 quarters. The position peaked at $2.65M in Q1 2022. 215 funds tracked by Wall St. Rank hold RVNC as of Q2 2023.

Prudential Financial reported no remaining Revance Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
Prudential Financial sold 8,963 Revance Therapeutics, Inc. shares in Q2 2023, an estimated $289K.
Prudential Financial first reported a position in Revance Therapeutics, Inc. in Q1 2020 and held it in 11 quarters.
Prudential Financial's Revance Therapeutics, Inc. position peaked at $2.65M in Q1 2022.
215 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2023.

Based on Prudential Financial's 13F filing for Q2 2023, filed 11 Aug 2023.